KR950703580A - CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments) - Google Patents

CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments) Download PDF

Info

Publication number
KR950703580A
KR950703580A KR1019950701273A KR19950701273A KR950703580A KR 950703580 A KR950703580 A KR 950703580A KR 1019950701273 A KR1019950701273 A KR 1019950701273A KR 19950701273 A KR19950701273 A KR 19950701273A KR 950703580 A KR950703580 A KR 950703580A
Authority
KR
South Korea
Prior art keywords
lys
glu
leu
ser
ala
Prior art date
Application number
KR1019950701273A
Other languages
English (en)
Korean (ko)
Inventor
람프라탭 에스 쿠시와하
헨리 씨 쥬니어 맥길
패트릭 칸다
Original Assignee
프랭크 에프. 레드포드, 쥬니어
사우쓰웨스트 파운데이션 퍼 바이오메디칼 리써치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프랭크 에프. 레드포드, 쥬니어, 사우쓰웨스트 파운데이션 퍼 바이오메디칼 리써치 filed Critical 프랭크 에프. 레드포드, 쥬니어
Publication of KR950703580A publication Critical patent/KR950703580A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1019950701273A 1993-08-04 1994-08-02 CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments) KR950703580A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10216093A 1993-08-04 1993-08-04
US08/102160 1993-08-04
PCT/US1994/008624 WO1995004755A1 (fr) 1993-08-04 1994-08-02 Polypeptide inhibiteur de cetp, anticorps contre ce polypeptide synthetique et traitements prophylactique et therapeutique de l'atherosclerose

Publications (1)

Publication Number Publication Date
KR950703580A true KR950703580A (ko) 1995-09-20

Family

ID=22288420

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701273A KR950703580A (ko) 1993-08-04 1994-08-02 CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments)

Country Status (6)

Country Link
EP (1) EP0664813A4 (fr)
JP (1) JPH08502525A (fr)
KR (1) KR950703580A (fr)
AU (1) AU683295B2 (fr)
CA (1) CA2145767A1 (fr)
WO (1) WO1995004755A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0831881T3 (da) 1995-06-06 2003-07-07 Avant Immunotherapeutics Inc CETP til forøgelse af HDL-cholesterolniveau
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904481A (en) * 1985-04-17 1990-02-27 The Board Of Trustess Of Leland Stanford University Method of conferring immuno-tolerance to a specific antigen
EP0618803A4 (fr) * 1991-12-19 1995-03-22 Southwest Found Biomed Res Polypeptide inhibant la proteine de transfert aux esters de cholesteryl, anticorps contre le polypeptide synthetique et traitements prophylactiques et therapeutiques anti-atherosclerose.

Also Published As

Publication number Publication date
EP0664813A1 (fr) 1995-08-02
JPH08502525A (ja) 1996-03-19
EP0664813A4 (fr) 1998-05-27
AU7552694A (en) 1995-02-28
CA2145767A1 (fr) 1995-02-16
WO1995004755A1 (fr) 1995-02-16
AU683295B2 (en) 1997-11-06

Similar Documents

Publication Publication Date Title
EP0477295B2 (fr) Inhibiteurs de l'agregation des plaquettes
US5935926A (en) Platelet aggregation inhibitors
Beil et al. Conformation dependence of antigenic determinants on the collagen molecule
US7094760B2 (en) Peptides for treatment of inflammation and shock
EP2327712A3 (fr) Traitement de maladies autoimmunes à l'aide du copolymère 1 et des copolymères et peptides apparentes
CA2155303A1 (fr) Traitement de diabetes a insulinodependance
ATE413189T1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
KR950701818A (ko) 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
JPH06504765A (ja) 新規抗血栓症物質
RU97105374A (ru) Модифицированные белки
CA2053799C (fr) Specificite pour les peptides synthetiques de la proteine basique anti-myeline presente dans le liquide cephalorachidien de patients atteints de la sclerose en plaques
US3864481A (en) Anti disease producing synthetic material for the prevention suppression and diagnosis of multiple sclerosis and method of treatment therefor
Timpl et al. Characterization of conformation independent antigenic determinants in the triple-helical part of calf and rat collagen
Bidart et al. Antigenic determinants on human choriogonadotropin alpha-subunit. I. Characterization of topographic sites recognized by monoclonal antibodies.
AU679913B2 (en) Stable polypeptide composition
US5344783A (en) Platelet aggregation inhibitors
KR950703580A (ko) CETP 억제 폴리펩티드, 그 합성 폴리펩티드에 대한 항체 및 아테롬성 동맥경화증의 예방학적 및 치료학적 처치(CETP Inhibitor Polypeptide, Antibodies against the Synthetic Polypeptide and Prophylactic and Therapeutic AntiAtheroselerosis Treatments)
Gregerson et al. Preparation, isolation, and immunochemical studies of the cyanogen bromide peptides from a retinal photoreceptor cell autoantigen, S-antigen.
Shohet et al. Localization of the human complement component C3 binding site on the IgG heavy chain.
US5514775A (en) Chromogranin peptides
JP2004525988A (ja) サイモシンβ４を用いる表皮水疱症（ＥｐｉｄｅｒｍｏｌｙｓｉｓＢｕｌｌｏｓａ）の治療
NZ324100A (en) Luminal cholecystokinin-releasing factor
WO1997015671A9 (fr) Facteur luminal liberant la cholecystokinine
Benson et al. Amino terminal sequence of amyloid P-component isolated from serum
ITMI20011833A1 (it) Agenti che regolano la permeabilita' vascolare

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid